#Denmark #Movement Disorders #Lundbeck #MSA #Valby

Lundbeck Showcases Progress in Movement Disorders

Lundbeck A/S is set to present groundbreaking data relating to its movement disorders pipeline at the upcoming International Congress of Parkinson's disease and Movement Disorders (MDS) 2026 in Seoul, South Korea, from October 4 to 8. The company is focusing on key areas such as Multiple System Atrophy (MSA) and advanced Parkinson's disease, addressing pressing challenges in treating these debilitating neurodegenerative conditions.

Advancements in Multiple System Atrophy

One of the highlights of Lundbeck's presentation includes a late-breaking oral presentation featuring the baseline characteristics of participants enrolled in the MASCOT study (NCT06706622). This ongoing Phase III trial aims to evaluate the efficacy and safety of amlenetug, a promising treatment for MSA. MASCOT includes a diverse cohort of 401 participants grappling with clinically probable or established MSA, specifically both MSA-C and MSA-P types. By enrolling a wide range of patients, the trial seeks to provide comprehensive insights into the safety and efficacy of the treatment over a rigorous 72-week double-blind period.

The severity of MSA, known for rapid progression and significant health burdens, necessitates innovative research. The ongoing investigations support the use of the modified Unified Multiple System Atrophy Rating Scale Part I (mUMSARS Part I) as a key clinical trial endpoint to measure functional decline in MSA patients. Furthermore, additional presentations will address healthcare utilization and costs associated with MSA, providing essential context for its healthcare burden in comparison to Parkinson's disease.

Insights into Parkinson's Disease Complications

Lundbeck will also highlight its exploratory Phase Ib trial data for Lu AF28996, an investigational drug designed for advanced Parkinson's disease patients facing challenging motor complications. In this 18-week open-label study, researchers evaluated the safety, tolerability, and clinical effects of this novel oral D1-like/D2-like dopamine receptor agonist on patients with inadequately controlled motor fluctuations.

The findings from this trial aim to shed light on the complex relationship between medication dosage, motor efficacy, and motor-related complications such as dyskinesia, which can severely impact patients’ lives. The clinical data will be supplemented by preclinical research involving a primate model, expanding understanding of how Lu AF28996 might contribute to better management of Parkinson's symptoms.

Commitment to Advancing Neuroscience

Tarek Samad, Executive Vice President and Head of Research Development at Lundbeck, emphasizes the need for continued innovation in these challenging areas of neuroscience. “Movement disorders such as MSA and Parkinson’s disease represent some of the most complex and high-need conditions in our field,” Samad stated. The breadth of research presented at MDS confirms Lundbeck’s commitment not only to drug development but also to the scientific understanding essential for devising effective treatments.

Lundbeck's science team will also share insights regarding potential cerebrospinal fluid biomarkers for disease detection and differential diagnosis of MSA. Given the complexity and overlapping symptoms with Parkinson's, these biomarkers could be crucial for early diagnosis and treatment customization.

Conclusion

The MDS 2026 congress serves as a crucial platform for Lundbeck to reiterate its commitment to transforming the landscape of treatment for movement disorders. As the company continues to spearhead research aimed at unmet needs in this space, the insights shared during the congress could pave the way for future advancements in the treatment of MSA and Parkinson's disease. Lundbeck's ongoing focus on clinical trials aims to improve the lives of countless individuals affected by these challenging conditions, and the data presented in Seoul could mark significant progress in understanding and treating these disorders.

With over 70 years dedicated to neuroscience, Lundbeck remains a focal innovator in the journey toward advancing brain health and transforming lives while tackling the pervasive impacts of neurological diseases.